Covenant Venture Capital has made a follow-on investment in Hill Research, the Princeton, New Jersey company building AI infrastructure for clinical trial biostatistics and regulatory workflows. Announced July 1, 2026, the second commitment follows roughly fourfold revenue growth at Hill Research from 2024 to 2025, according to the release.
The New Jersey Economic Development Authority’s Evergreen Innovation Fund participated as a limited partner in Covenant. Hill Research is also a Jetstream Venture Fund portfolio company.
How TriClick Automates Statistical Programming for FDA Submissions
Before a new therapy reaches regulators, statistical programmers must convert a locked clinical database into the tables, figures, and listings (TFLs) that support an FDA filing. The work demands precision and traceability, and delays add time and cost to drug development.
Hill Research’s TriClick platform automates that pipeline. The company reports delivering TFL packages 300 times faster, with significantly fewer errors and fully traceable outputs. Covenant cited Hill Research’s execution across product development, customer acquisition, and revenue, and said new capital will support TriClick adoption, platform development, and commercial expansion.
Recognition in Clinical AI
Hill Research was named to New Jersey’s 2026 Innovate100. In January 2026, its AI team presented three research projects at the 40th AAAI Conference on Artificial Intelligence in Singapore, where CEO Dr. Louise Liu delivered a keynote.
About Hill Research
Led by founder and CEO Dr. Louise Liu, Hill Research is an AI-powered clinical research company that pairs automation with human oversight for compliance and quality. Jetstream invested in Hill Research in April 2026. Read why Jetstream invested in Hill Research.
Frequently Asked Questions
What is Hill Research’s TriClick platform?
TriClick is Hill Research’s AI platform for clinical trial biostatistics. It automates statistical programming and regulatory submission work, turning a locked clinical database into FDA submission-ready tables, figures, and listings, which the company says it delivers 300 times faster.
Why did Covenant make a follow-on investment in Hill Research?
Covenant reinvested after evaluating Hill Research’s execution since its initial commitment, including roughly fourfold revenue growth from 2024 to 2025 and growing TriClick adoption among pharmaceutical, biotechnology, and clinical research organizations. The investment amount was not disclosed.
Read the Original Article: Covenant Makes Follow-On Investment in Hill Research, Citing Fourfold Revenue Growth and Accelerating Market Adoption
